EQS-News: NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE

EQS

Im Artikel erwähnte Wertpapiere: STRATEC N

EQS-News: STRATEC SE / Key word(s): Personnel
NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE

01.12.2022 / 16:14 CET/CEST
The issuer is solely responsible for the content of this announcement.


NEW APPOINTMENT TO BOARD OF MANAGEMENT OF STRATEC SE

Birkenfeld, December 1, 2022

The Supervisory Board of STRATEC SE, Birkenfeld, Germany, (Frankfurt: SBS; Prime Standard, SDAX) has decided to extend the company’s Board of Management with a further member and appointed Dr. Georg Bauer to the Board with responsibility for sales as of January 1, 2023. Dr. Bauer will strengthen the existing team on the Board of Management, which already includes Marcus Wolfinger, Dr. Robert Siegle, and Dr. Claus Vielsack.

Dr. Bauer (49) has gained more than 20 years of professional experience in senior positions at technology companies with international operations. He was most recently Director of the Smart Consumables business unit and Managing Director of STRATEC Consumables GmbH, a global OEM player in the field of smart consumables for applications in diagnostics, life sciences, and medical technology. Dr. Bauer studied chemistry at Vienna University, where he obtained his doctorate in biochemistry and bioanalytical systems.

“We are delighted to welcome a proven expert in our industry to the Board of Management. Dr. Bauer has both longstanding sales experience with highly complex system solutions and all-round expertise in developing and manufacturing micro-fluidic and smart consumables. He is ideally qualified to further expand and strengthen the STRATEC Group’s leading market position as a one-stop provider of in-vitro diagnostics automation solutions. Working as a team, the Board of Management will make every effort to enable us to continue on our successful growth course and optimally satisfy our customers’ needs”, comments Marcus Wolfinger, Chief Executive Officer of STRATEC SE.

ABOUT STRATEC
STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange and are listed in the SDAX select index of the German Stock Exchange.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler | Investor Relations, Sustainability & Corporate Communications
Tel: +49 7082 7916-6515
ir@stratec.com
www.stratec.com



01.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1503357

 
End of News EQS News Service

1503357  01.12.2022 CET/CEST

Im Artikel erwähnte Wertpapiere

STRATEC N 85,80 -1,15%
close

Populäre Aktien